All In Biotech

NDA 021351 · Allergan

Oxytrol

Oxybutynin · Transdermal · Cholinergic Muscarinic Antagonist

Last checked: Nov 20, 2026Latest source record: May 29, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Feb 26, 2003

Approved uses

1

Original approval plus efficacy supplements

Registered trials

103

25 Phase 3, 9 recruiting

FAERS reports

23,120

13,881 serious, 1,707 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 29, 2024.

OXYTROL is a muscarinic antagonist indicated for the treatment of overactive bladder in men with symptoms of urge urinary incontinence, urgency, and frequency. OXYTROL is a muscarinic antagonist indicated for the treatment of overactive bladder in men with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 )

Mechanism: The free base form of oxybutynin is pharmacologically equivalent to oxybutynin hydrochloride. Oxybutynin acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle. In patients with conditions characterized by involuntary detrusor contractions, cystometric studies have demonstrated that oxybutynin increases maximum urinary bladder capacity and increases the volume to first detrusor contraction. Oxybutynin is a racemic (50:50) mixture of R- and S-isomers. Antimuscarinic activity resides predominantly in the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • OXYTROL · OXYBUTYNIN 3.9MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Oxybutynin" as an intervention, any sponsor and status, largest first.

All 103 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,792
  • fatigue1,543
  • fall1,497
  • nausea1,185
  • diarrhoea1,075
  • urinary tract infection1,053
  • dizziness1,039
  • pain1,012
  • headache949
  • off label use930
  • asthenia903
  • dyspnoea757

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004203
2005250
2006188
200773
200880
2009123
2010370
2011595
2012739
2013746
20141,222
20151,549
20161,829
20171,897
20182,032
20192,072
20201,786
20211,489
20221,470
20231,370
20241,014
20251,179
2026843

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Oxytrol (Oxybutynin)

2024 spending

$1.4M

Beneficiaries

425

1,434 claims

Per beneficiary

$3,248

$82.99 per unit

View as table
YearSpending
2020$2,942,541
2021$2,587,140
2022$2,200,353
2023$1,799,809
2024$1,380,315

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 392 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.